Parallel imaging and a 32-channel coil help modality gain the upper hand over FDG-PET/CT
A preliminary trial at University Hospitals Munich has established MRI's ascendancy for 32 patients. Thirteen received whole-body MRI and FDG-PET/CT to diagnose suspected bone metastases from primary breast cancers. Six had a gastrointestinal tumor, and another six had cancers with an unknown primary origin. Other patients were diagnosed with lymphoma, hepatocellular carcinoma, sarcoma, or melanoma.
Whole-body MRI and FDG-PET/CT showed 91% and 78% accuracy, respectively, in identifying 127 bone lesions. MRI's sensitivity of 94% was significantly better than PET/CT's 78%. Although PET/CT was more specific (80% versus 76%), the difference was not significant, said chief investigator Dr. Gerwin P. Schmidt.
The superior performance of whole-body MRI was independent of lesion size, although MRI tended to detect small lesions that whole-body PET/CT missed. MRI was more accurate in eight out of nine anatomic regions. PET/CT performed slightly better in the lower spine, while the two modalities had problems finding small lesions in the upper shoulder and rib cage. Four metastases that were identified with whole-body MRI in the distal femur were not observed with PET/CT because of field-of-view limitations, Schmidt said.
A 32-channel radiofrequency coil array that provided 205 cm of coverage, combined with parallel imaging acceleration, boosted performance of the 1.5T scanner, Schmidt said. T1-weighted coronal imaging was performed in five stages that were then reconstructed to produce whole-body images. Sagittal T1-weighted and short-tau inversion recovery images were also acquired during abdominal and pelvic stages. The average room time for a scan was 45 minutes.
Whole-body PET/CT involved 200 MBq of FDG. Low-dose CT for attenuation correction preceded an emission scan with a 3D reconstruction algorithm; a diagnostic CT in late venous phase at 130 mA/130 kVp was also performed. Time in the room averaged 103 minutes.
Despite the results, Schmidt stopped short of recommending that whole-body MRI replace FDG-PET/CT for this application.
"The two techniques are complementary, but using both brings in the matter of cost," he said.
Emerging MRI Scoring System May Help Predict Recurrent and Metastatic Hepatocellular Carcinoma
February 12th 2025Preoperative use of the scoring system for gadoxetic acid-enhanced MRI demonstrated an average AUC of 85 percent and average specificity of 89 percent in external validation cohorts for pathologic features of hepatocellular carcinoma.
Can MRI-Based Deep Learning Improve Risk Stratification in PI-RADS 3 Cases?
January 30th 2025In external validation testing, a deep learning model demonstrated an average AUC of 87.6 percent for detecting clinically significant prostate cancer (csPCA) on prostate MRI for patients with PI-RADS 3 assessments.